Cowen Upgrades Biogen (BIIB) to Outperform, After FDA Approval Received For Aduhelm
Tweet Send to a Friend
Cowen analyst Phil Nadeau upgraded Biogen (NASDAQ: BIIB) from Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
